AIF1 and COVID-19: We found that both markers were reduced in the gray matter in the frontal cortex and hippocampus in DS COVID + cases, whereas others reported increases in the number of nodes of activated microglia labeled with Iba-1 and alterations in BBB integrity in postmortem brains of patients with AD and COVID-19 [29].